MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED
MK-2870-019
Phase 3 small_molecule active
Quick answer
MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED for Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2]) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active